Last reviewed · How we verify

NCT06137040

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

Recruiting now EARLY_PHASE1 Last updated 6 December 2024
What this trial tests

EARLY_PHASE1 trial testing Magnesium Sulfate within the first hour in Asthma in Children in 100 participants. Currently enrolling.

Timeline
30 November 2023
Primary endpoint
31 May 2025
31 May 2025

Quick facts

Lead sponsorUniversity of Oklahoma
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment100
Start date30 November 2023
Primary completion31 May 2025
Estimated completion31 May 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Oklahoma

Who can join

Adults 5 to 17, any sex, with Asthma in Children or Asthma Attack. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma in Children

Currently open trials in the same condition.

Other University of Oklahoma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing